2019 - 2022 Elucidation of the molecular mechanism of CYP3A4 induction in the human intestine and its differences from the liver
2019 - 2021 ヒト腸管におけるCYP3A4誘導の分子機序及び肝臓との異同の解明
2017 - 2020 Nuclear receptor PXR-mediated hepatocyte proliferation: understanding of its mechanism and human relevance
2017 - 2020 Development of evaluation methods for drug-induced liver injury based on both chemical structure/biological reactivity of drugs and individual factors
2016 - 2019 Elucidation of mechanisms underlying different glucocorticoid responses of drug-metabolizing enzymes, SULT1E1 and CYP3A7, in human fetal liver cells
2011 - 2012 Understanding of molecular mechanism and development of prediction system of drug- induced hepatotoxicity, focusing on the inflammation-associated nuclear receptors and cell-cell interactions.
2010 - 2012 Understanding of the mechanism for the nuclear receptor-mediated hepatotoxicity and establishment of the prediction and evaluation system for the toxicity.
2010 - 2011 CYP3A4 induction-associated dyslipidemia : a new risk factor for lifestyle disease
2009 - 2011 Regulation of hepatic lipid metabolism through ileal bile acid-FGF signaling
2008 - 2011 The role and crosstalk between nuclear receptors PXR and CAR on the pathogenesis of non-alcoholic steatohepatitis.
2008 - 2010 Role of ileal bile acid absorption on regulation of serum cholesterol levels
2007 - 2008 Role of nuclear receptors PXR and CAR under the energy surplus condition such as obesity
2007 - 2008 Mechanisms for delayed organ toxicity induced by drug and prediction system using comprehensive analysis
2006 - 2007 The role of nuclear receptor CAR in the pathogenesis of non-alcoholic Steatohepatitis
2004 - 2005 Induction of CAR and the nuclear localization are promoted in HepG2 hepatoma cells arrested at G_1 phase of cell cycle : Association with gene expression of UGT1A1 and Gadd45β
2003 - 2005 Guanylate cyclase-cyclic GMP signaling pathway in platelet disaggregation associated with dissociation of PAF-receptor complex
2002 - 2003 Study on defect in human UGTIAI gene promoter associated with hyperbilirubinemia and mechanism of the UGTIAI in duction
Show all
Papers (166)：
Kaori Ambe, Mizuki Nakamori, Riku Tohno, Kotaro Suzuki, Takamitsu Sasaki, Masahiro Tohkin, Kouichi Yoshinari. Machine Learning-Based In Silico Prediction of the Inhibitory Activity of Chemical Substances Against Rat and Human Cytochrome P450s. Chemical research in toxicology. 2024
Hideaki Yokoyama, Taku Masuyama, Yuki Tanaka, Taishi Shimazaki, Yuzo Yasui, Takuya Abe, Kouichi Yoshinari. Diacylglycerol O-acyltransferase 1 inhibitor increases plasma alanine aminotransferase and aspartate aminotransferase activities via a shedding of the intestinal villi and an increase in intestinal permeability in rats. Toxicology letters. 2024. 400. 16-23
Takumi Sato, Ryota Shizu, Ryonosuke Baba, Akira Ooka, Takuomi Hosaka, Yuichiro Kanno, Kouichi Yoshinari. Pregnane X receptor inhibits the transdifferentiation of hepatic stellate cells by downregulating periostin expression. The Biochemical journal. 2024. 481. 18. 1173-1186
Haruka Tsutsui, Motohiro Kato, Shino Kuramoto, Kouichi Yoshinari. Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice. Drug metabolism and pharmacokinetics. 2024. 57. 101010-101010
Yasushi Yamazoe, Yoshiya Yamamura, Kouichi Yoshinari. Construction of a fused grid-based CYP2C8-Template system and the application. Drug metabolism and pharmacokinetics. 2024. 55. 100492-100492
佐藤拓海, 志津怜太, 保坂卓臣, 佐々木崇光, 菅野裕一朗, 吉成浩一. Mechanism of the nuclear receptor PXR-mediated suppression of transdifferentiation of hepatic stellate cells. 日本薬学会年会要旨集(Web). 2023. 143rd
Kouichi Yoshinari, Ryota Shizu. Special Section on Drug Metabolism and Regulation-Minireview. DRUG METABOLISM AND DISPOSITION. 2022. 50. 7. 1019-1026
志津怜太, 佐藤拓海, 三浦佳恵, 保坂卓臣, 菅野裕一朗, 佐々木崇光, 吉成浩一. Screening of nuclear receptor CAR and PPARα activation potential of chemicals which cause liver cancer in rat carcinogenicity test. 衛生薬学・環境トキシコロジー講演要旨集. 2022. 2022
佐藤拓海, 志津怜太, 志津怜太, 馬場遼之介, 石村麻衣, 保坂卓臣, 保坂卓臣, 佐々木崇光, 菅野裕一朗, 菅野裕一朗, et al. Mechanism of the nuclear receptor PXR-mediated suppression of epithelial-mesenchymal transition of liver cancer cells. 日本薬学会年会要旨集(Web). 2022. 142nd
馬場遼之介, 志津怜太, 佐藤拓海, 保坂卓臣, 菅野裕一朗, 吉成浩一. Evaluation of the influence of PXR activation on epithelial-mesenchymal transition of liver cancer cells using reporter assay with the VIMENTIN promoter. 衛生薬学・環境トキシコロジー講演要旨集. 2022. 2022
Classification of toxicological findings observed in repeated-dose toxicity tests by using statistical analysis with toxicity test database
(EuroTox2018 2018)
Education (2)：
1993 - 1998 Tohoku University Graduate School of Pharmaceutical Sciences
1989 - 1993 Tohoku University Faculty of Pharmaceutical Sciences
Professional career (1)：
博士(薬学) (東北大学)
Work history (3)：
2006/04 - 2014/03 Tohoku University Graduate School of Pharmaceutical Sciences
2001/10 - 2006/03 University of Shizuoka School of Pharmaceutical Sciences
1998/04 - 2001/09 NIEHS/NIIH
Committee career (10)：
2024/07 - 現在 日本毒性学会 理事
2023/11 - 現在 日本動物実験代替法学会 理事
2020/11 - 現在 日本動物実験代替法学会 代議員
2017/12 - 現在 日本薬物動態学会 理事
2016/10 - 現在 厚生労働省 化学物質のリスク評価検討会委員
2015/02 - 現在 日本薬学会 代議員
2014/07 - 現在 日本毒性学会 評議員
2013/10 - 現在 内閣府食品安全委員会 専門委員
2018/07 - 2022/06 日本毒性学会 理事
2011/01 - 2021/01 厚生労働省 薬事・食品衛生審議会臨時委員
Show all
Awards (5)：
2024/07 - 日本毒性学会 日本毒性学会学会賞(第18回)
2018/03 - 日本薬学会 学術振興賞
2017/07 - 日本毒性学会 第3回日化協LRI賞
2011/04 - ISSX ISSX Asia-Pacific New Investigator Award
2009/10 - 日本薬物動態学会(JSSX) 奨励賞
Association Membership(s) (9)：
THE INTERNATIONAL SOCIETY FOR THE STUDY OF XENOBIOTICS
, THE SOCIETY OF TOXICOLOGY
, THE CHEM-BIO INFORMATICS SOCIETY
, THE JAPANESE BIOCHEMICAL SOCIETY
, THE JAPANESE CANCER ASSOCIATION
, THE JAPANESE SOCIETY FOR ALTERNATIVES TO ANIMAL EXPERIMENTS
, THE JAPANESE SOCIETY OF TOXICOLOGY
, THE JAPANESE SOCIETY FOR THE STUDY OF XENOBIOTICS
, THE PHARMACEUTICAL SOCIETY OF JAPAN
